NCT01185990

Brief Summary

The study is designed to identify specific patterns of brain functional activity associated with chronic, moderate to severe tinnitus through the use of resting-state MEG scans. Robust patterns identified in this study will be used as a biomarker for subsequent clinical evaluation of experimental drug treatments for tinnitus. This study will conduct MEG scans on approximately 30 to 75 subjects with tinnitus and approximately 15 healthy control subjects. MEG scans will be obtained for each subject following screening, clinical and tinnitus evaluations. A subset of 6 subjects from the tinnitus cohort will be invited to undergo evoked auditory assessment during an extended MEG scan session to identify cortical regions that respond to the auditory stimulus. These six subjects also will be evaluated with a single structural MRI scan to support high-resolution mapping of the localized cortical regions. MEG data will be analyzed to identify patterns of brain activity that are specifically associated with the presence of tinnitus using both standard approaches and the Orasi Synchronous Neural Interaction™ (SNI) test. MEG scan results also will be evaluated to identify specific patterns of functional activity that correlate with other measures of tinnitus severity such as the Iowa Tinnitus Handicap Scale. This study will test the hypothesis that moderate to severe tinnitus is associated with altered patterns of brain functional activity measured by a brief, resting-state MEG scan. This hypothesis will be tested by comparing resting-state MEG scans of tinnitus patients with those the of healthy control subjects collected during this study and available in Orasi's existing MEG scan database.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
45

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2010

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

August 17, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 20, 2010

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2011

Completed
Last Updated

March 23, 2011

Status Verified

March 1, 2011

Enrollment Period

1 year

First QC Date

August 17, 2010

Last Update Submit

March 22, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Correlated brain activity

    MEG scan data will be analyzed using standard frequency domain approaches and the Orasi SNI test for correlated, synchronous activity.

    1 day

Secondary Outcomes (1)

  • Tinnitus Severity Ratings

    Up to 14 days

Study Arms (2)

Tinnitus subjects

Subjects with chronic, moderate to severe unilateral tinnitus.

Healthy control subjects

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects with chronic, moderate to severe unilateral tinnitus

You may qualify if:

  • Subject is between 18 and 75 years of age at the time of screening.
  • Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
  • Subject is a non-smoker.
  • Subject is judged to be in good health based on medical history and brief physical examination.
  • Subject has a diagnosis of chronic, moderate to severe (Tinnitus Handicap Inventory score range of 38 - 76, inclusive), unilateral tinnitus of unknown etiology, or is participating in the study as a healthy control subject.

You may not qualify if:

  • Subject has severe hearing impairment, external or middle ear diseases or temporomandibular joint disorders.
  • Subject has a diagnosis of a significant neurological condition including Alzheimer's disease, Parkinson's disease, vascular dementia, Lewy body dementia or frontal temporal dementia, human immunodeficiency virus, multiple sclerosis, or severe traumatic brain injury.
  • Subject has a history of primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder, delusional disorder) or bipolar disorder.
  • Subject has a history of seizures, epilepsy, stroke, peripheral neuropathy, head trauma with persistent post-concussive symptoms, ADHD, dyslexia or other clinically significant neurological disease or cognitive impairment.
  • Subject has a current episode of major depressive disorder.
  • Subject has used antidepressants, anxiolytics, antipsychotics or antiepileptic medications in the past 6 months.
  • Subject has a recent (within 2 years) history of alcohol or substance abuse/dependence.
  • Subject has completed an MRI within 2 weeks prior to the MEG scan.
  • Subject has metal braces or pacemaker that may interfere with the MEG scan.
  • Subject is unable to complete the MEG scan procedure.
  • The investigator has any concern regarding the safe participation of a subject in the study, or if for any other reason the investigator considers the subject inappropriate for study participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Noran Neurological Clinic

Minneapolis, Minnesota, 55407, United States

RECRUITING

Radiant Research

Minneapolis, Minnesota, 55435, United States

RECRUITING

MeSH Terms

Conditions

Tinnitus

Condition Hierarchy (Ancestors)

Hearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Richard E Golden, MD

    Noran Neurological Clinic

    PRINCIPAL INVESTIGATOR
  • Tami Helmer, MD

    Radiant Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

August 17, 2010

First Posted

August 20, 2010

Study Start

August 1, 2010

Primary Completion

August 1, 2011

Study Completion

August 1, 2011

Last Updated

March 23, 2011

Record last verified: 2011-03

Locations